Na+ sensitive hypertension in Dahl salt sensitive rats (Dahl S) or spontaneously hypertensive rats (SHR) is linked to intrinsic changes in the brain that favour increased Na+ entry into the cerebrospinal fluid (CSF) followed by increases in sympathetic hyperactivity and hypertension (Huang et al 2004). Similar responses are observed in salt resistant and Wistar rats that receive an intracerebroventricular (icv) infusion of Na+ rich artificial cerebrospinal fluid (aCSF) (Huang et al 2001, 2006). Downstream to increased CSF[Na+], a pathway has been described involving mineralocorticoid receptors (MRs), benzamil sensitive Na+ channels, “ouabain”, and angiotensin II type 1 receptors (AT1-R) (Huang et al 1998, Zhao et al 2001, Wang and Leenen 2003, Huang et al 2008). Blood pressure (BP) responses to increased CSF[Na+] may involve activation of AT1-R in the subfornical organ (SFO) as the BP response to injection of NaCl into a lateral ventricle can be blocked by AT1-R blockade in the SFO (Rohmeiss et al 1995a). The role of aldosterone and AT1-R in the SFO was investigated in mediating the BP and heart rate (HR) response to increases in CSF[Na+] and local [Na+]. Results show that infusion of 0.45M and 0.6M Na+ rich aCSF into the SFO increases BP but not HR. The BP is unchanged by infusion of a mannitol solution osmotically equivalent to 0.6M Na+ rich aCSF indicating that the SFO is Na+ sensitive. The BP response to a lower concentration of Na+ (0.45M) is enhanced by prior infusion of aldosterone while BP response to 0.6M is not further enhanced suggesting that the SFO may have maximal responsiveness to acute increases in [Na+] at 0.6M. The BP responses to Na+ rich aCSF in the SFO and the enhancement of those responses by aldosterone can be blocked by infusion of the AT1-R blocker Candesartan in the SFO. This response appears therefore to be mediated in the SFO through AT1-R activation, likely through Ang II release in the SFO. ICV infusion of Na+ rich aCSF increases BP but not HR and this response is partially blocked by infusion of the AT1-R blocker Candesartan in the SFO. This indicates that nearly half the BP responses to icv infusion of Na+ rich aCSF is mediated through AT1-R activation in the SFO. Lastly, contrary to icv, PVN and MnPO studies (Huang and Leenen 1996, Budzikowski and Leenen 2001, Gabor and Leenen 2009) ouabain in the SFO does not increase BP or HR. In conclusion, these results show that the SFO is Na+ sensitive and mediates half the BP responses to changes in CSF[Na+] through a mechanism that involves AT1-R activation. The SFO is further sensitized to Na+ by aldosterone presumably through its genomic effects. Lastly, ouabain in the SFO does not increase BP or HR suggesting that endogenous ouabain in the SFO is not involved in modulating BP or HR responses.

Angiotensin II (Ang II) is an important modulator for development of atherosclerosis from early stage foam cell formation to advanced stage plaque rupture. Recently, the importance of locally generated Ang II, especially in macrophages, has become more evident. Generation of Ang II by several enzymes other than ACE and renin has been shown mainly in vitro. Cathepsin G is one these enzymes which is expressed in neutrophils and macrophages. Macrophages are one of the primary and crucial cells in atherosclerotic lesions which become lipid-laden foam cells through lipoprotein uptake. We hypothesized that activation of nuclear factors in foam cells increases Ang II by modulation of the renin angiotensin system (RAS) genes and cathepsin G. We also hypothesized that cathepsin G, through its Ang II generating activity and its other catalytic functions, promotes atherosclerosis. The present study assessed the Ang I and II levels and expression of the RAS genes in THP-1 cells, a human acute monocytic leukemia cell line, and in peritoneal and bone marrow-derived macrophages after exposure to acetylated LDL (ac-LDL). I also evaluated how RAS blockade would affect foam cell formation in THP-1 cells. In parallel, I assessed the role of cathepsin G in Ang II generation and in the progression of atherosclerosis in cathepsin G heterozygous knockout mice on an Apoe-/- background (Ctsg+/-Apoe-/- mice). Ac-LDL treatment increased Ang I and Ang II levels in cell lysates and media from THP-1 cells but not in peritoneal or bone marrow-derived macrophages from wild type C57BL/6 mice. In ac-LDL-treated THP-1 cells, ACE and cathepsin G mRNA levels and activities were elevated. Angiotensinogen mRNA is increased but not the angiotensinogen protein concentration. Renin mRNA level and activity were not altered by ac-LDL treatment. Blocking RAS by an AT1 receptor blocker, ACE inhibitors or a renin inhibitor decreased cholesteryl ester content of THP-1 cells after exposure to ac-LDL. To confirm that the Ang II effect on foam cell formation was not unique to ac-LDL, we treated the THP-1 macrophages with a renin inhibitor or an AT1 receptor inhibitor after exposure to oxidized LDL (ox-LDL). RAS blockade in ox-LDL-treated cells also abolished cholesteryl ester formation. To see how Ang II plays a role in foam cell formation we assessed the effect of RAS inhibitors on SR-A, the principal receptor for mediating ac-LDL entry into the cells and on acyl-CoA:cholesterol acyl transferase (ACAT-1), the enzyme responsible for intracellular cholesterol esterification. RAS blockade in both ac-LDL- and ox-LDL-treated cells decreased SR-A and ACAT-1 protein levels. Cathepsin G partial deficiency on an Apoe-/- background did not change Ang II levels in peritoneal or bone marrow-derived macrophage cell lysates or media. This deficiency also did not affect immunoreactive angiotensin peptide levels in atherosclerotic lesions. After 8 weeks on a high fat diet Ctsg+/-Apoe-/- mice were similar to Ctsg+/+Apoe-/- mice in terms of lesion size and serum cholesterol levels but the Ctsg+/+Apoe-/- mice had more advanced lesions with more collagen and smooth muscle cells and fewer macrophages. Moreover, Ctsg+/+Apoe-/- mice had more apoptotic cells than their Ctsg+/-Apoe-/- littermates. Overall, our findings indicate that Ang II is increased in foam cells and this endogenous Ang II is involved in cholesteryl ester formation, possibly by regulating the levels of ACAT-1 and SR-A. We did not find any role for cathepsin G in generation of Ang II in mice but cathepsin G does, nevertheless, promote the progression of atherosclerotic lesions to a more advanced stage.

Thesis (Ph. D.)--University of Washington, 2001. / Vita. Includes bibliographical references (leaves 98-109).

Not available / text

Angiotensin II (Ang II) is an important modulator for development of atherosclerosis from early stage foam cell formation to advanced stage plaque rupture. Recently, the importance of locally generated Ang II, especially in macrophages, has become more evident. Generation of Ang II by several enzymes other than ACE and renin has been shown mainly in vitro. Cathepsin G is one these enzymes which is expressed in neutrophils and macrophages. Macrophages are one of the primary and crucial cells in atherosclerotic lesions which become lipid-laden foam cells through lipoprotein uptake. We hypothesized that activation of nuclear factors in foam cells increases Ang II by modulation of the renin angiotensin system (RAS) genes and cathepsin G. We also hypothesized that cathepsin G, through its Ang II generating activity and its other catalytic functions, promotes atherosclerosis. The present study assessed the Ang I and II levels and expression of the RAS genes in THP-1 cells, a human acute monocytic leukemia cell line, and in peritoneal and bone marrow-derived macrophages after exposure to acetylated LDL (ac-LDL). I also evaluated how RAS blockade would affect foam cell formation in THP-1 cells. In parallel, I assessed the role of cathepsin G in Ang II generation and in the progression of atherosclerosis in cathepsin G heterozygous knockout mice on an Apoe-/- background (Ctsg+/-Apoe-/- mice). Ac-LDL treatment increased Ang I and Ang II levels in cell lysates and media from THP-1 cells but not in peritoneal or bone marrow-derived macrophages from wild type C57BL/6 mice. In ac-LDL-treated THP-1 cells, ACE and cathepsin G mRNA levels and activities were elevated. Angiotensinogen mRNA is increased but not the angiotensinogen protein concentration. Renin mRNA level and activity were not altered by ac-LDL treatment. Blocking RAS by an AT1 receptor blocker, ACE inhibitors or a renin inhibitor decreased cholesteryl ester content of THP-1 cells after exposure to ac-LDL. To confirm that the Ang II effect on foam cell formation was not unique to ac-LDL, we treated the THP-1 macrophages with a renin inhibitor or an AT1 receptor inhibitor after exposure to oxidized LDL (ox-LDL). RAS blockade in ox-LDL-treated cells also abolished cholesteryl ester formation. To see how Ang II plays a role in foam cell formation we assessed the effect of RAS inhibitors on SR-A, the principal receptor for mediating ac-LDL entry into the cells and on acyl-CoA:cholesterol acyl transferase (ACAT-1), the enzyme responsible for intracellular cholesterol esterification. RAS blockade in both ac-LDL- and ox-LDL-treated cells decreased SR-A and ACAT-1 protein levels. Cathepsin G partial deficiency on an Apoe-/- background did not change Ang II levels in peritoneal or bone marrow-derived macrophage cell lysates or media. This deficiency also did not affect immunoreactive angiotensin peptide levels in atherosclerotic lesions. After 8 weeks on a high fat diet Ctsg+/-Apoe-/- mice were similar to Ctsg+/+Apoe-/- mice in terms of lesion size and serum cholesterol levels but the Ctsg+/+Apoe-/- mice had more advanced lesions with more collagen and smooth muscle cells and fewer macrophages. Moreover, Ctsg+/+Apoe-/- mice had more apoptotic cells than their Ctsg+/-Apoe-/- littermates. Overall, our findings indicate that Ang II is increased in foam cells and this endogenous Ang II is involved in cholesteryl ester formation, possibly by regulating the levels of ACAT-1 and SR-A. We did not find any role for cathepsin G in generation of Ang II in mice but cathepsin G does, nevertheless, promote the progression of atherosclerotic lesions to a more advanced stage.

Diss. (sammanfattning) Uppsala : Univ., 2002. / Härtill 4 uppsatser.

Zsfassung in dt. Sprache. - Würzburg, Univ., Diss., 2008

Thesis (M. Phil.)--University of Hong Kong, 2009. / Includes bibliographical references (leaves 121-143). Also available in print.

Thesis (Ph. D.)--University of Hong Kong, 2009. / Includes bibliographical references. Also available in print.

Thesis (Ph.D.) - University of Queensland, 2005. / Includes bibliography.